




atrogenic hypoglycemia is the limiting factor in the
glycemic management of diabetes (1,2). It causes
recurrent morbidity in most people with type 1
diabetes as well as many with advanced type 2
diabetes and is sometimes fatal. It precludes maintenance
of euglycemia over a lifetime of diabetes and, therefore,
full realization of the beneﬁts of glycemic control. It
compromises physiological and behavioral defenses against
subsequent falling plasma glucose concentrations and thus
causes a vicious cycle of recurrent hypoglycemia. Insight into
the pathophysiology of glucose counterregulation will con-
tinue to lead to understanding of the frequency and impact
of, risk factors for, and prevention of iatrogenic hypoglyce-
mia (1,2).
Marked absolute therapeutic hyperinsulinemia can
cause isolated episodes of hypoglycemia in people with
diabetes. However, episodes of hypoglycemia are more
typically the result of the interplay of relative or mild-
moderate absolute therapeutic hyperinsulinemia and com-
promised physiological and behavioral defenses against
falling plasma glucose concentrations (1,2) (Fig. 1). The
compromised physiological defenses include loss of dec-
rements in -cell insulin, loss of increments in -cell
glucagon, and, given the latter, attenuation of increments
in adrenomedullary epinephrine. The compromised behav-
ioral defense is the failure of carbohydrate ingestion
resulting from loss of symptoms, which is largely the
result of an attenuated sympathetic neural response. The
concept of hypoglycemia-associated autonomic failure
(HAAF) in diabetes posited, initially, that recent anteced-
ent hypoglycemia causes both defective glucose counter-
regulation (by attenuating the epinephrine response in the
setting of absent insulin and glucagon responses) and
hypoglycemia unawareness (by attenuating largely the
sympathetic neural and resulting symptomatic responses)
and thus also causes a vicious cycle of recurrent hypogly-
cemia (1,2). The original concept of hypoglycemia-related
HAAF was subsequently expanded to include exercise-
related and sleep-related HAAF (1,2).
The mechanism(s) of the key feature of these three
types of HAAF in diabetes—an attenuated sympathoadre-
nal response to falling plasma glucose concentrations—is
not known. That of hypoglycemia-related HAAF has been
hypothetically attributed to 1) increased cortisol secretion
during recent antecedent hypoglycemia, 2) increased
blood-to-brain glucose transport resulting from recent
antecedent hypoglycemia, or 3) effects of recent anteced-
ent hypoglycemia on hypothalamic, or perhaps a cerebral
network, functions (1,2).
With respect to the former mechanism, Davis et al.
(3) reported that cortisol elevations, produced by corti-
sol infusions in a dose of 2.0 g  kg
1  min
1 o v e r2h
two times reduced the plasma epinephrine, norepineph-
rine, muscle sympathetic nerve activity, and pancreatic
polypeptide responses to hypoglycemia the following day
in nondiabetic humans. Therefore, they suggested that it is
the increase in circulating cortisol, acting on the brain,
during recent antecedent hypoglycemia that reduces the
sympathoadrenal (adrenal medullae and sympathetic neu-
ral) as well as the parasympathetic neural responses to
subsequent hypoglycemia. That notion was seemingly sup-
ported by the ﬁnding that pharmacological cortisol hyper-
secretion, produced by 1–24ACTH infusions, reduced the
sympathoadrenal (plasma epinephrine, norepinephrine,
and symptomatic) and parasympathetic (plasma pancre-
atic polypeptide) responses to hypoglycemia the following
day (4). However, the interpretation of the original data (3)
was undercut by the ﬁndings 1) that cortisol elevations
comparable with those that occur during hypoglycemia
did not reduce the sympathoadrenal and symptomatic
responses to subsequent hypoglycemia (5,6) and 2) that
blockade of cortisol secretion (with metyrapone) did not
prevent the effect of recent antecedent hypoglycemia to
reduce the plasma epinephrine responses to hypoglycemia
the following day in humans (6).
Obviously, the mechanisms of hypoglycemia-related,
exercise-related, and sleep-related HAAF need not be the
same. For example, recent antecedent hypoglycemia and
prior exercise involve previous cortisol elevations but
sleep-related HAAF does not (1,2).
The risk of hypoglycemia during or shortly after exer-
cise, particularly in people with insulin-treated diabetes, is
generally recognized (1,2). The risk of hypoglycemia oc-
curring several hours after exercise, and thus often during
the night (1,2,7,8), is less widely appreciated. In one series of
patients with type 1 diabetes, one-quarter suffered nocturnal
hypoglycemia in the absence of afternoon exercise and
one-half suffered nocturnal hypoglycemia in the presence of
afternoon exercise (8). That follows directly from the phys-
iology of glucose counterregulation in nondiabetic individu-
als (9) and its pathophysiology during exercise in absolutely
endogenous insulin-deﬁcient diabetes: type 1 or advanced
type 2 diabetes (10,11). In the setting of absent insulin and
glucagon responses to falling glucose levels, attenuated sym-
pathoadrenal responses are reduced further after exercise
(10). Such patients have exercise-related HAAF.
In this issue of Diabetes, Bao et al. (12) report that
cortisol elevations comparable with those that occur
during hypoglycemia produced by cortisol infusions in a
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1  min
1 over 2 h two times, reduce
the plasma epinephrine, norepinephrine, and pancreatic
polypeptide responses to exercise the following day in pa-
tients with type 1 diabetes. These data suggest that prior
stress-related cortisol elevations, such as those during hypo-
glycemia, might be one factor contributing to the pathogen-
esis of exercise-related HAAF. However, an effect of prior
cortisol elevations to reduce symptoms, an important feature
of HAAF, was not reported. In addition, an effect of inhibition
of prior cortisol synthesis to improve defenses against sub-
sequent exercise-related HAAF was not provided.
Clearly, iatrogenic hypoglycemia is a problem for people
with diabetes that has not been solved. Pending the preven-
tion and cure of diabetes and the development of methods
that provide plasma glucose–regulated insulin replacement
or secretion, innovative research in humans as well as in
experimental animals is needed if we are to eliminate hypo-
glycemia from the lives of people affected by diabetes.
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FIG. 1. Schematic representation of the components of hypoglycemia-associated autonomic failure in diabetes (1,2). TD1M, type 1 diabetes;
T2DM, type 2 diabetes.
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